Their joint aim is to identify new therapeutic targets in ‘triple negative’ breast cancers Curie-Cancer, the body which leads the Institut Curie's industry partner research activity, and Servier, today announce that they have ...
Tags: triple negative, Curie-Cancer, TTK/MPS1, Institut Curie and Servier
BIND Therapeutics, a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins, has amended its development and commercialization collaboration agreement with Amgen to extend the period ...
Roche and Prothena have agreed to jointly develop and commercialize new antibodies that target alpha-synuclein, including PRX002, Prothena's monoclonal antibody for the treatment of Parkinson's disease (PD). Currently, PRX002 is in ...
Canada-based ImStar Therapeutics has announced the selection of IMS-088 as its lead drug candidate for the treatment of amyotrophic lateral sclerosis. IMS-088 is a novel, small-molecule drug that stems from the discovery of a new target ...
US-based biotechnology firm Ignyta has entered into a license agreement with Nerviano Medical Sciences (Nerviano), under which Ignyta will get exclusive global development and marketing rights of tyrosine kinase inhibitors RXDX-101 and ...
Tags: Ignyta, Tyrosine Kinase Inhibitors
Fidelity Biosciences, a subsidiary of Fidelity Investments, and US-based Regenx Biosciences have announced the formation of Dimension Therapeutics, a gene therapy company focused on developing novel treatments for rare diseases. Dimension ...
Tags: Biosciences, Health, Medicine
AstraZeneca has selected an undisclosed oncology target from Regulus Therapeutics as part of their strategic alliance in order to discover, develop and commercialize microRNA therapeutics. Both the companies have entered into a strategic ...
AstraZeneca's global biologics research and development division MedImmune will acquire Spirogen, a biotech firm focused on antibody-drug conjugate technology for use in oncology. Spirogen's complete shares will be purchased by MedImmune ...
Tags: biologics research, AstraZeneca
Biopharmaceutical company Soligenix has secured a contract worth $6.4m from the US Department of Health and Human Service's National Institutes of Health (NIH), for the advanced preclinical development of OrbeShield (oral beclomethasone ...
Genmab and ADC Therapeutics have partnered to co-develop a new antibody-drug conjugate (ADC) product conjugate to treat multiple cancer indications. The collaboration will integrate Genmab's high-affinity fully human antibody targeting ...
Tags: Genmab, ADC Partner
US-based biopharmaceutical company Acadia Pharmaceuticals's glaucoma collaboration partner Allergan has advanced a new additional drug candidate into preclinical development for the treatment of glaucoma. Acadia CEO Uli Hacksell said that ...
Tags: Preclinical Development, Allergan
Nimbus Discovery, a US-based biotechnology company, has entered into a co-development agreement with Shire aiming at small molecule treatments for lysosomal storage disorders (LSDs), which are considered as the rare genetic diseases. The ...
Belgium-based clinical stagebiopharmaceutical company arGEN-X has progressed its fourth therapeutic candidate, ARGX-112, into formal preclinical development. The new human antibody ARGX-112 neutralizes both IL20 and IL22 signaling through ...
Tags: preclinical development, clinical stagebiopharmaceutical, Medicine
The US Patent and Trademark Office (USPTO) has issued new patent covering OXiGENE benzosuberene-based compounds and methods of using them in tubulin polymerization inhibition. The patent protects benzosuberene-based compounds including ...
Tags: Health, OXiGENE, Oxigene Benzosuberene-Based Compounds
Tranzyme Pharma has completed the chemistry-based drug discovery partnership and transferred the resulting compounds to Bristol-Myers Squibb to advance the development. The strategic collaboration leveraged Macrocyclic Template Chemistry, ...
Tags: Tranzyme Pharma, chemistry based drug, chemistry technology, company news